
VERAXA Biotech Advances VXA-222 Cancer Program and Expands Patent Portfolio
VERAXA Biotech's progress on its VXA-222 bispecific ADC program and expanded intellectual property underscores its commitment to developing next-generation cancer therapies.
Read full story






















